The UK's NICE has approved AstraZeneca and Daiichi Sankyo's breast cancer drug Enhertu for NHS use in England, expanding access to approximately 1,000 patients annually following revised cost-effectiv
AstraZeneca shares fell 10% after its nerve drug Wainua failed a Phase III heart disease trial, erasing $20 billion in market value. Investors now await results from key oncology trials SERENA-4 and A
The FTSE 100 fell 0.6% amid Middle East tensions, dragged down by AstraZeneca after its nerve disease drug failed a late-stage trial. Oil prices rose marginally following U.S. strikes on Iran, impacti
European stocks rose led by tech rebounds, while crude oil dipped amid Middle East tensions. AstraZeneca shares fell 8% after its nerve disease drug Wainua failed late-stage cardiovascular trials.
ChemBrief